Generics BulletinTariffs are a key topic these days at biopharma events and things were no different at Cipla’s annual general meeting (AGM), especially amid US president Donald Trump’s continued threat and changing t
ScripTariffs are a key topic these days at biopharma events and things were no different at Cipla’s annual general meeting (AGM), especially amid US President Donald Trump’s continued threat and changing t
ScripFrontline Indian firms appear keen to accelerate product in-licensing deals with foreign companies and these efforts have now evolved from a “supplementary tactic” to a cornerstone of their strategy,
Pink SheetThe European Medicines Agency has begun reviewing a new batch of products for potential pan-EU marketing approval, including LIB Therapeutics’ lerodalcibep for treating primary hypercholesterolemia or